source
- Lilly beats forecasts while Novo Nordisk misses sales and trial targetsEli Lilly reported second-quarter revenue of nearly $23 billion, up 48% year-over-year, easily surpassing analysts’ $20.6 billion estimate. The boost came from continued strength of its tirzepatide…
- Attovia Therapeutics raises $289 million in IPO to fund antibody-drug research for skin and inflammatory diseasesAttovia Therapeutics completed an IPO raising $289 million, selling 17 million shares at $17 each and valuing the company at $767 million. Shares will begin trading on Nasdaq under the ticker ATTO.…